Search clinical trials for: Pemetrexed/ Cisplatin

Total 3997 results

University Health Network, Toronto
Eli Lilly and Company

Terminated

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Mesothelioma | Pleural Mesothelioma

Canada
Masonic Cancer Center, University of Minnesota

Completed

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Prostate Cancer | Mesothelioma

United States
Eli Lilly and Company

Completed

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Malignant Pleural Mesotherioma

Japan
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
ARCAGY/ GINECO GROUP

Completed

CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto

Cervix Cancer

France
Fudan University

Completed

Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)

Lung Adenocarcinoma

China
Chonnam National University Hospital
Pusan National University Hospital; Korea University Guro Hospital; Kyungpook... and other collaborators

Completed

Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung (APICAL)

Adenocarcinoma | Lung Neoplasm

Korea, Republic of
Samsung Medical Center

Unknown

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Aduro Biotech, Inc.

Completed

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Mesothelioma | Mesothelioma, Malignant | Malignant Mesothelioma | Peritoneal Mesothelioma | Malignant Peritoneal Mesothelioma

United States
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.; GeneCast Biotechnology Co., Ltd.

Enrolling by invitation

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (APEX)

Non-small Cell Lung Carcinoma

China
Columbia University

Terminated

Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Pleural Mesothelioma

United States
Centre Hospitalier Intercommunal Creteil
Groupe Français de Pneumo-Cancérologie

Terminated

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (METAL2)

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Cerebral Metastases | Adenocarcinoma of Lung Metastatic to Brain

France
Bristol-Myers Squibb

Completed

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (CheckMate 568)

Non-Small-Cell Lung Cancer

United States, Canada
Eli Lilly and Company

Completed

A Study in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, Germany
Hoffmann-La Roche

Completed

AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

France, Germany, Spain, Sweden, Russian Federation, Greece, Switzerland, Korea, Republic of, Italy, Netherlands, Turkey, United Arab Emirates
Hoffmann-La Roche

Completed

A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Belgium, Spain, United Kingdom, Germany, Italy, Poland, France
Morphotek

Completed

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma (Amatuximab)

Malignant Pleural Mesothelioma

United States, Canada, Germany, Spain, Netherlands
Bayer

Completed

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Medical Oncology

United States, Italy
Fifth Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (Neoafa)

Chemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
Rachel Sanborn
AstraZeneca; Providence Cancer Center, Earle A. Chiles Research Institute

Active, not recruiting

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Lung Cancer | Non-small Cell Carcinoma

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Solid Cancers

United States, Spain
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Morphotek

Terminated

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) (ARTEMIS)

Mesothelioma, Malignant

France, United Kingdom, United States, Germany, Australia, Italy
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; United States Department of Defense

Completed

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Lung Cancer

United States
Canadian Cancer Trials Group
AstraZeneca

Completed

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Non-Small Cell Lung Cancer

Canada
Eli Lilly and Company

Completed

A Study in Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

Argentina, Israel, United States, Spain, Germany, Belgium, Italy, Brazil, France, Canada, Netherlands, Turkey
Merck Sharp & Dohme LLC

Completed

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

Advanced Cancer
Guangzhou Institute of Respiratory Disease

Not yet recruiting

Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC

Staging IV NSCLC

China
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Singapore, Taiwan
National Cancer Institute (NCI)

Completed

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Neoplasms

United States
Biotheus Inc.

Recruiting

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

MPM

China
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Sichuan Kelun Pharmaceutical Research Institute...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Non-small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

NSCLC | EGF-R Positive Non-Small Cell Lung Cancer

China
Eli Lilly and Company

Completed

Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Cancer

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

Lung Cancer

United States, Australia
Boehringer Ingelheim

Terminated

BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, Greece, Hungary, France, Italy, Poland
Institut für Klinische Krebsforschung IKF GmbH...
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Pleural Mesothelioma Malignant

Germany
Eli Lilly and Company

Completed

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

Belgium, France, Germany, Portugal, Spain, Sweden, Italy, United States, Canada, Netherlands, Argentina, Australia, Austria, Brazil, Denmark, Finland, Greece, Hungary, India, Israel, Korea, Republic of, Mexico, Poland, Puerto Rico, Taiwan, Turk... and more
Medical University of South Carolina

Terminated

Cisplatin and Pemetrexed With Radiation Followed by Lobectomy (CisPemXetSrg)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Nonsmall Cell Lung Cancer Stage III

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Cervical Cancer

United States
Peking University Cancer Hospital & Institute

Recruiting

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoIpower)

Non-Small Cell Lung Cancer

China
Eli Lilly and Company

Completed

A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, Italy, Germany, France
Istituto Scientifico Romagnolo per lo Studio e...
Pierre Fabre Laboratories

Terminated

Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression (HighTySy)

Carcinoma, Non-Small-Cell Lung | Secondary | Advanced Stage IIIB | High Thymidylate Synthase Expression

Italy
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Transgene

Terminated

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME)

Non-Small-Cell Lung Carcinoma

United States, France, Hungary, United Kingdom, Spain, Israel, Belgium, Germany, Poland, Italy

Search clinical trials for: Pemetrexed/ Cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations